Steering through complexity: management approaches in multiple sclerosis

被引:11
作者
Cree, Bruce A. C. [1 ]
Hartung, Hans-Peter [2 ,3 ]
机构
[1] Univ Calif San Francisco, Dept Neurol, Multiple Sclerosis Ctr, 675 Nelson Rising Lane,Box 3206, San Francisco, CA 94158 USA
[2] Univ Dusseldorf, Dept Neurol, Fac Med, Dusseldorf, Germany
[3] Univ Dusseldorf, Fac Med, Ctr Neuropsychiat, Dusseldorf, Germany
关键词
multiple sclerosis disease-modifying therapies; multiple sclerosis treatment algorithm; progressive multifocal leukoencephalopathy; DISEASE-ACTIVITY; GLATIRAMER ACETATE; DOUBLE-BLIND; NATALIZUMAB TREATMENT; NO EVIDENCE; PATIENT; TERIFLUNOMIDE; MULTICENTER; SAFETY; TOLERABILITY;
D O I
10.1097/WCO.0000000000000332
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose of review This review evaluates current and late-phase developing therapies for multiple sclerosis in regard to therapeutic efficacy and patient safety in light of recent published and presented observations from 2015. Recent findings We describe data that provide supportive evidence for comparisons of therapeutic efficacy of multiple sclerosis therapies and review available data on rare but serious adverse events associated with these therapies. Summary Serious adverse events that are sometimes rare and unpredictable may substantially alter current approaches to multiple sclerosis treatments. New therapies that have proved superior effects compared with older therapies will also impact multiple sclerosis treatment practice in the near future.
引用
收藏
页码:263 / 271
页数:9
相关论文
共 50 条
[41]   Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango [J].
Gupta, Sahil ;
Weinstock-Guttman, Bianca .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (01) :115-126
[42]   Multiple Sclerosis [J].
Schiess, Nicoline ;
Calabresi, Peter A. .
SEMINARS IN NEUROLOGY, 2016, 36 (04) :350-356
[43]   LSN MS guidelines for the management of multiple sclerosis [J].
Shatila, A. R. ;
Koussa, S. ;
Jabbour, R. ;
Mourad, A. ;
Aouad, A. ;
Sabbagh, G. ;
Kallab, K. ;
Hilal, R. ;
Khalifeh, R. ;
Gebeily, S. ;
Tourbah, A. .
REVUE NEUROLOGIQUE, 2013, 169 (12) :950-955
[44]   The management of multiple sclerosis in children: a European view [J].
Ghezzi, Angelo ;
Banwell, Brenda ;
Boyko, Alexey ;
Amato, Maria Pia ;
Anlar, Banu ;
Blinkenberg, Morten ;
Boon, Maartje ;
Filippi, Massimo ;
Jozwiak, Sergiusz ;
Ketelslegers, Immy ;
Kornek, Barbara ;
Lim, Ming ;
Lindstrom, Eva ;
Nadj, Congor ;
Neuteboom, Rinze ;
Rocca, Maria A. ;
Rostasy, Kevin ;
Tardieu, Marc ;
Wassmer, Evangeline ;
Catsman-Berrevoets, Coriene ;
Hintzen, Rogier .
MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (10) :1258-1267
[45]   Role of oral teriflunomide in the management of multiple sclerosis [J].
Tanasescu, Radu ;
Evangelou, Nikos ;
Constantinescu, Cris S. .
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2013, 9 :539-553
[46]   Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis [J].
Wiendl, Heinz ;
Meuth, Sven G. .
DRUGS, 2015, 75 (09) :947-977
[47]   Infection Risk in Patients on Multiple Sclerosis Therapeutics [J].
Williamson, Eric M. ;
Berger, Joseph R. .
CNS DRUGS, 2015, 29 (03) :229-244
[48]   Evolving concepts in the treatment of relapsing multiple sclerosis [J].
Comi, Giancarlo ;
Radaelli, Marta ;
Sorensen, Per Soelberg .
LANCET, 2017, 389 (10076) :1347-1356
[49]   Pediatric multiple sclerosis Escalation and emerging treatments [J].
Chitnis, Tanuja ;
Ghezzi, Angelo ;
Bajer-Kornek, Barbara ;
Boyko, Alexey ;
Giovannoni, Gavin ;
Pohl, Daniela .
NEUROLOGY, 2016, 87 (09) :S103-S109
[50]   Pathogenetic treatment of multiple sclerosis: the present and the future [J].
Boyko, A. N. ;
Stolyarov, I. D. ;
Sidorenko, T. V. ;
Kulakova, O. V. ;
Kolyak, E. V. ;
Petrov, A. M. ;
Ilves, A. G. ;
Nikiforova, I. G. ;
Favorova, O. O. ;
Gusev, E. I. .
ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2009, 109 (07) :90-+